CSF1R Fusion

CI-VAR-00001160Explore in graph →CIViC 30

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
MEF2D::CSF1R Fusion	GW-2580 + ImatinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID403 Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580. PMID 24186003 · Lilljebjörn et al., 2014 · Open in CIViC	civic
B Lymphoblastic Leukemia/Lymphoma1
MEF2D::CSF1R Fusion	Panobinostat	Predictive	D	Supports Sensitivity Response	3	submitted	EID9359 In this study, 560 cases of B-ALL were analyzed by RNAseq, 22 (3.9%) of which (3.9%) demonstrated rearrangements of MEF2D at chromosome 1q21–22, encoding myocyte enhancer factor 2D, representing 15 of… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like1
MEF2D::CSF1R Fusion	Imatinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID9360 This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specific… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC	civic